Cancer research
Long-Term Responses to Regorafenib in Metastatic Colorectal Cancer Patients Analyzed in New Study
Researchers at Bayer HealthCare Pharmaceuticals Inc. have published a study on the long-term responses of patients with metastatic colorectal cancer (mCRC) treated with regorafenib. The study, published in the journal Cancers, analyzed a database of 2444 patients who initiated regorafenib monotherapy between 2013 and 2023. The research found that patients